Video

Dr. Tannir on CANTATA study of telaglenastat plus cabozantinib in mRCC

Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Video Player is loading.
Current Time 0:00
Duration 4:45
Loaded: 0%
Stream Type LIVE
Remaining Time 4:45
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Nizar M. Tannir, MD, MD Anderson Cancer Center, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma who progressed on immune checkpoint inhibitors or antiangiogenic therapies.

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    © 2025 MJH Life Sciences

    All rights reserved.